← back to search

Carlos Gallardo

Fundación Arturo López Pérez ·
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, and HER2/EGFR in Cancer Research.
h-index
3
citations
2,850
works
5
NIH funding
—
primary concept
Pembrolizumab
email
✉ Find email ↗

Recent publications

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
New England Journal of Medicine 2022cited by 1,053position: middledoi
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
The Lancet 2020cited by 1,776position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Oleg Lipatov · Republican Oncological Clinical Dispensary1 papers (2022–2022)Hiroji Iwata · Juntendo University1 papers (2022–2022)Sherene Loi · Peter MacCallum Cancer Centre1 papers (2022–2022)Erhan Gokmen · Ege University1 papers (2022–2022)Mastura Md Yusof · National Cancer Centre Japan1 papers (2022–2022)Wilbur Pan · Merck & Co., Inc., Rahway, NJ, USA (United States)1 papers (2022–2022)Marco Torregroza Otero · Cancer Research Institute1 papers (2022–2022)Javier Cortés · Universidade Nova de Lisboa1 papers (2022–2022)David W. Cescon · University Health Network1 papers (2022–2022)Norikazu Masuda · Kyoto University1 papers (2022–2022)Seock‐Ah Im · Seoul National University1 papers (2022–2022)Xuan Zhou · University of Edinburgh1 papers (2022–2022)Vassiliki Karantza · Merck & Co., Inc., Rahway, NJ, USA (United States)1 papers (2022–2022)José Manuel Pérez-García · Asociación Española Contra el Cáncer1 papers (2022–2022)Hope S. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center1 papers (2022–2022)Carlos H. Barrios · Centro Brasileiro de Estudos em Dermatologia1 papers (2022–2022)Zifang Guo · Beijing Chemical Industry Research Institute (China)1 papers (2022–2022)Peter Schmid · Cancer Research Institute1 papers (2022–2022)